As of June 21, 2025, Kiwa Bio-Tech Products Group Corp (KWBT) reports a ROE (Return on Equity) of -68.51%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Kiwa Bio-Tech Products Group Corp's ROE (Return on Equity)
Over recent years, Kiwa Bio-Tech Products Group Corp's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2019-12-31 | -68.51% |
| 2018-12-31 | 2.70% |
| 2017-12-31 | 49.75% |
| 2016-12-31 | -20.99% |
| 2015-12-31 | 6.10% |
This slight downward trend highlights how Kiwa Bio-Tech Products Group Corp manages its efficiency in generating profits from shareholders' equity over time.
Comparing Kiwa Bio-Tech Products Group Corp's ROE (Return on Equity) to Peers
To better understand Kiwa Bio-Tech Products Group Corp's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Kiwa Bio-Tech Products Group Corp (KWBT) | -68.51% |
| Aziyo Biologics Inc (AZYO) | 653.63% |
| Multicell Technologies Inc (MCET) | 263.43% |
| Rasna Therapeutics Inc (RASP) | 227.13% |
| Biosyntech Inc (BSYI) | 194.35% |
| Immune Therapeutics Inc (IMUN) | 140.69% |
Compared to its competitors, Kiwa Bio-Tech Products Group Corp's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.